HighTower Advisors’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$307K Buy
12,551
+3,262
+35% +$90.8K ﹤0.01% 3199
2026
Q2
$319K Sell
9,289
-799
-8% -$24.1K ﹤0.01% 3164
2026
Q1
$240K Sell
10,088
-316
-3% -$8.77K ﹤0.01% 3350
2025
Q4
$288K Sell
10,404
-32
-0.3% -$816 ﹤0.01% 3077
2025
Q3
$253K Buy
+10,436
New +$208K ﹤0.01% 3183
2022
Q2
– Sell
-4,352
Closed -$251K – 3253
2022
Q1
$251K Buy
4,352
+576
+15% +$37.8K ﹤0.01% 2658
2021
Q4
$301K Buy
+3,776
New +$323K ﹤0.01% 2469

Other funds holding BEAM

HighTower Advisors's BEAM Position: Q3 2026 in Review

HighTower Advisors increased its Beam Therapeutics (BEAM) stake by 35% in Q3 2026, buying an estimated $90.8K and bringing the position to 12,551 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #3199.

HighTower Advisors first reported a position in BEAM in Q4 2021 and has held it in 7 quarters since. The position peaked at $319K in Q2 2026. 260 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • HighTower Advisors held 12,551 shares of Beam Therapeutics worth $307K as of Q3 2026.
  • HighTower Advisors bought 3,262 Beam Therapeutics shares in Q3 2026, an estimated $90.8K.
  • Beam Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3199 holding.
  • HighTower Advisors first reported a position in Beam Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • HighTower Advisors's Beam Therapeutics position peaked at $319K in Q2 2026.
  • 260 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.